Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Laronidase | Aldurazyme | 4.4 Special Warnings and Special Precautions for Use, 4.8 Undesirable effects, 4.9 Overdose | Hypersensitivity reactions, IARs, Immunogenicity, Oedema peripheral, injection site pain, Warn healthcare providers about inappropiate administration leading to gastrointestinal adverse reactions, headache, dizziness, and dyspnea | Apr,2023 |
| Triptorelin | Decapeptyl | "4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects" | Idiopathic intracranial hypertension | Feb,2023 |
| Levofloxacin | Tavanic | 4.4. Special warnings and precautions for use | Aortic Aaneurysm and Ddissection, and heart valve regurgitation/incompetence | Mar,2024 |
| Secukinumab | Cosentyx | 4.8 Undesirable effects | Pyoderma gangrenosum | Feb,2023 |
| Nirmatrelvir/Ritonavir | Paxlovid | 4.5. Interactions with other medicinal products | Interactions with Sirolimus | Apr,2023 |
| Vardenafil | Levitra | 4.4 Special warnings and precautions for use, 4.5. Interactions with other medicinal products" | Interactions with strong Cytochrome (CYP3A4) inhibitors or moderate Cytochrome (CYP3A4) increases plasma concentrations of vardenafil Cobicistat with Vardenafil can result in increased plasma concentrations of Vardenafil | Apr,2023 |